La gripe: 76 años de vacuna antigripal… ¡y de la hemaglutinina!
PDF

Palabras clave

Gripe
vacuna
actualidad
futuro

Cómo citar

Navarro Alonso, J. A. (2020). La gripe: 76 años de vacuna antigripal… ¡y de la hemaglutinina!. Revista Madrileña De Salud Pública, 3(11), 1–8. https://doi.org/10.36300/remasp.2020.056

Resumen

Se revisa someramente la historia de los virus gripales y los pasos dados desde que se utilizó masivamente la primera vacuna de virus completos, hasta la descripción de las distintas vías de vehiculizar o de administrar la hemaglutinina de las que disponemos en la actualidad, en aras de mejorar la respuesta inmune y por tanto la protección clínica de toda la población.

Se exponen brevemente los requisitos que debería cumplir una futura vacuna “universal” para que pudiera ser usada con carácter sistemático y los distintos proyectos en marcha.

https://doi.org/10.36300/remasp.2020.056
PDF

Citas

Hannoun C. The evolving history of influenza viruses and influenza vaccines. Expert Rev Vaccines 2013;12(9):1085-1094. https://doi.org/10.1586/14760584.2013.824709

Barberis I, Myles P, Ault S et al. History and evolution of influenza control through vaccination: from the first monovalent vaccine to universal vaccines. J Prev Med Hyg 2016; 57(3): E115-E120.

Centers for Disease Control and Prevention [Internet]. Influenza historic timeline. [Consultado el 25 de febrero de 2020]. Disponible en: https://www.cdc.gov/flu/pandemic-resources/pandemic-timeline-1930-and-beyond.htm

Weir JP, Gruber MF. An overview of the regulation of influenza vaccines in the United States. Influenza Other Respir Viruses. 2016; 10(5):354-360. https://doi.org/10.1111/irv.12383

Kilbourne E, Smith C, Brett I et al. The total influenza vaccine failure of 1947 revisited: major intrasubtypic antigenic change can explain failure of vaccine in a post-World War II epidemic. PNAS. 2002 ;99(16):10748-10752. https://doi.org/10.1073/pnas.162366899

World Health Organization. A revision of the system of nomenclature for influenza viruses: a WHO memorandum. Bull World Health Organ 1980; 58(4):585-591.

Hampson AW. Vaccines for pandemic influenza. The history of our current vaccines, their limitations and the requirement to deal with a pandemic threat. Ann Acad Med Singapore. 2008; 37(6):722-730.

Eichelberger MC, Monto AS. Neuraminidase, the forgotten surface antigen, emerges as an influenza vaccine target for broadened protection. J Infect Dis 2019;219(S1): S75-80. https://doi.org/10.1093/infdis/jiz017

Yamayoshi S, Kawaoka. Current and future influenza vaccines. Nat Med. 2019; 25:212-220. https://doi.org/10.1038/s41591-018-0340-z

Pebody R, Whitaker H, Zhao H et al. Protection provided by influenza vaccine against influenza-related hospitalization in ≥65 year olds: early experience of introduction of a newly licensed adjuvanted vaccine in England in 2018/19. Vaccine 2020; 38(2):173-179. https://doi.org/10.1016/j.vaccine.2019.10.032

Domnich A, Arata L, Amicizia D, Puig-Barberá J, Gasparini R, Panatto D. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: a systematic review and meta-analysis. Vaccine. 2017; 35(4):513-520. https://doi.org/10.1016/j.vaccine.2016.12.011

Hung I, Yuen K. Immunogenicity, safety and tolerability of intradermal influenza vaccines. Hum Vacc Immunother. 2018; 14(3):565-570. https://doi.org/10.1080/21645515.2017.1328332

Chung J, Flannery B, Thompson M et al. Seasonal effectiveness of live attenuated and inactivated influenza vaccine in infants and young children. Pediatrics. 2016;137(2): e20153279. https://doi.org/10.1542/peds.2015-3279

Navarro Alonso JA. Efectividad de la vacuna antigripal atenuada en la infancia. En: Campins Marti M y Moraga Llop F, editores. Vacunas 2017.Madrid: Undergraf;2017.

American Academy of Pediatrics. Recommendations for prevention and control of influenza in children 2019-2020. Pediatrics. 2109;144(4): e20192478. https://doi.org/10.1542/peds.2019-2478

Pebody R, Zhao H, Whitaker H et al. Effectiveness of influenza vaccine in children in preventing influenza associated hospitalization, 2018/19, England. Vaccine. 2020; 38 (2):158-164. https://doi.org/10.1016/j.vaccine.2019.10.035

Dunkle L, Izikson R, Patriarca P et al. Efficacy of recombinant influenza vaccine in adults 50 years of age or older. N Eng J Med. 2017; 376(25):2427-2436. https://doi.org/10.1056/NEJMoa1608862

Díaz Granados C, Dunning A, Kimmel M et al. Efficacy of high dose versus standard-dose influenza vaccine in older adults. N Eng J Med. 2014; 371(7):635-645. https://doi.org/10.1056/NEJMoa1315727

Izurieta HS, Thadani N, Shay DK, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. Lancet Infect Dis. 2015; 15(3):293-300. https://doi.org/10.1016/S1473-3099(14)71087-4

Lu Y, Chillarige Y, Izurieta H et al. Effect of age on relative effectiveness of high-dose versus standard-dose influenza vaccines among US medicare beneficiaries aged ≥65 years. J Infect Dis. 2019; 220(9):1511-1520. https://doi.org/10.1093/infdis/jiz360

García A, Arístegui J, Moreno D et al. Documento de reflexión sobre la vacunación antigripal tetravalente. Madrid 2019. Disponible en: https://www.semg.es/images/2019/Documentos/doc_reflexion_vac_grip_trivalente_2019.pdf

Caini S, Kusznierz G, Vera Garate V et al. The epidemiological signature of influenza B virus and its B/Victoria and B/Yamagata lineages in the 21st century. PLoS ONE. 2019;14(9): e0222381. https://doi.org/10.1371/journal.pone.0222381

Gaglani M, Vasudevan A, Raiyani Ch et al. Effectiveness of trivalent and quadrivalent inactivated vaccines against influenza B in the United States, 2011-12 to 2016-17. Epub ahead of print, 2020 Feb 1. Clin Infect Dis. 2020; ciaa102. https://doi.org/10.1093/cid/ciaa102

Skowronski DM, Chambers C, De Serres G et al. Vaccine effectiveness against lineage-matched and-mismatched influenza B viruses across 8 seasons in Canada, 2010-2011 to 2017-2018. Clin Infect Dis 2019; 68(10):1754-1757. https://doi.org/10.1093/cid/ciy876

Rondy M, Kissling E, Dorthe-Emborg H et al. Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five european studies. Euro Surveill. 2018;23(9):pii=18-00086. https://doi.org/10.2807/1560-7917.ES.2018.23.9.18-00086

Pebody R, Djennad A, Ellis J et al. End of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18. Euro Surveill. 2019;24(31):pii=1800488. https://doi.org/10.2807/1560-7917.ES.2019.24.31.1800488

World Health Organization [Internet]. Recommended composition of influenza virus vaccine for use in the 2020-2021 northern hemisphere influenza season. [Consultado el 25 de febrero de 2020] Disponible en: https://www.who.int/influenza/vaccines/virus/recommendations/202002_recommendation.pdf?ua=1

Zost SJ, Parkhouse K, Gumina ME et al. Contemporary H3N2 influenza viruses have a glycosilation site that alters binding of antibodies elicited by egg-adapted vaccine strain. PNAS. 2017; 114(47):12578-12583. https://doi.org/10.1073/pnas.1712377114

Skowronski D, Hottes T, De Serres G et al. Influenza B/Victoria antigen induces strong recall of B/Yamagata but lower B/Victoria response in children primed with two doses of B/Yamagata. Pediatr Infect Dis J. 2011; 30(10): 833-889. https://doi.org/10.1097/INF.0b013e31822db4dc

Monto A, Petrie J. Improving influenza vaccine effectiveness: ways to begin solving the problem. Clin Infect Dis, 2019 :69(10):1824-1826. https://doi.org/10.1093/cid/ciz416

Valkenburg S, Cowling B. Turning influenza vaccinology on its head to reveal the stalk. Lancet Infect Dis 2020; 20(1):5-7. https://doi.org/10.1016/S1473-3099(19)30556-0

Erbelding E, Post D, Stemmy E et al. A universal influenza vaccine: the strategic plan for the National Institute of Allergy and Infectious Diseases. J Infect Dis. 2018; 218 (3):347-354. https://doi.org/10.1093/infdis/jiy103

Plotting a route to a universal influenza vaccine. Lancet Infect Dis. 2018; 18(5):475-476. https://doi.org/10.1016/S1473-3099(18)30235-4

Henry C, Palm AE, Krammer F, Wilson PC et al. From original antigenic sin to the universal influenza virus vaccine. Trends Immunol. 2018; 39(1):70-79. https://doi.org/10.1016/j.it.2017.08.003

De Vries R, Nieuwkoop N, van der Klis F, Koopmans MPG, Krammer F, Rimmelzwaan GF. Primary human influenza B virus infection induces cross-lineage hemnaglutinin stalk-specific antibodies mediating antibody-dependent celular citotoxicity. J Infect Dis. 2017; 217:3-11. https://doi.org/10.1093/infdis/jix546

Bernstein D, Guptill J, Naficy A et al. Immunogenicty of chimeric haemaglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial. Lancet Infect Dis. 2020; 20(1) :80-91. https://doi.org/10.1016/S1473-3099(19)30393-7

Eichelberger M, Morens D, Taubenberger J. Neuraminidase as an influenza vaccine antigen: a low hanging fruit, ready to picking to improve vaccine effectiveness. Curr Op Immunol. 2018; 53:38-44. https://doi.org/10.1016/j.coi.2018.03.025

Chen Y, Wohbold T, Zheng N et al. Influenza infections in humans induce broadly cross-reactive and protective neuraminidase-reactive antibodies. Cell. 2018;173(2):417-429. https://doi.org/10.1016/j.cell.2018.03.030

Estrada L, Schultz-Cherry S. Development of a universal influenza vaccine. J Immunol. 2019; 202 (2):392-398. https://doi.org/10.4049/jimmunol.1801054

Paules C, Fauci A. Influenza vaccines: good, but we can do better. J Infect Dis. 2019;219 (S1): S1-S4. https://doi.org/10.1093/infdis/jiy633

El autor/autores retienen los derechos de propiedad intelectual sobre sus trabajos. La reutilización de los trabajos puede hacerse en los términos de la Licencia Creative Commons Atribución-NoComercial-SinDerivadas 4.0 International.

En caso de que el trabajo presentado sea aprobado para su publicación, como autor(es) y propietario(s) de los derechos de autor, autorizan de manera ilimitada en el tiempo a la REMASP para que pueda reproducirlo, editarlo, distribuirlo, exhibirlo y comunicarlo en el país y en el extranjero por medio electrónico.

Los autores firmantes reconocen que REMASP asume como suyos los principios del acceso abierto establecidos en las declaraciones de Berlín, Bethesda y Budapest; razón por la cual aceptan que el trabajo que se presenta sea distribuido en acceso abierto, resguardando los derechos de autor bajo una licencia “Creative Commons”.

Descargas

Los datos de descargas todavía no están disponibles.